BACKGROUND: Most lung cancers are attributed to smoking. These cancers have been associated with multiple genetic alterations and with the presence of preneoplastic bronchial lesions. In view of such associations, we evaluated the status of specific chromosomal loci in histologically normal and abnormal bronchial biopsy specimens from current and former smokers and specimens from nonsmokers. METHODS: Multiple biopsy specimens were obtained from 18 current smokers, 24 former smokers, and 21 nonsmokers. Polymerase chain reaction-based assays involving 15 polymorphic microsatellite DNA markers were used to examine eight chromosomal regions for genetic changes (loss of heterozygosity [LOH] and microsatellite alterations). RESULTS: LOH and microsatellite alterations were observed in biopsy specimens from both current and former smokers, but no statistically significant differences were observed between the two groups. Among individuals with a history of smoking, 86% demonstrated LOH in one or more biopsy specimens, and 24% showed LOH in all biopsy specimens. About half of the histologically normal specimens from smokers showed LOH, but the frequency of LOH and the severity of histologic change did not correspond until the carcinoma in situ stage. A subset of biopsy specimens from smokers that exhibited either normal or preneoplastic histology showed LOH at multiple chromosomal sites, a phenomenon frequently observed in carcinoma in situ and invasive cancer. LOH on chromosomes 3p and 9p was more frequent than LOH on chromosomes 5q, 17p (17p13; TP53 gene), and 13q (13q14; retinoblastoma gene). Microsatellite alterations were detected in 64% of the smokers. No genetic alterations were detected in nonsmokers. CONCLUSIONS: Genetic changes similar to those found in lung cancers can be detected in the nonmalignant bronchial epithelium of current and former smokers and may persist for many years after smoking cessation.
BACKGROUND: Most lung cancers are attributed to smoking. These cancers have been associated with multiple genetic alterations and with the presence of preneoplastic bronchial lesions. In view of such associations, we evaluated the status of specific chromosomal loci in histologically normal and abnormal bronchial biopsy specimens from current and former smokers and specimens from nonsmokers. METHODS: Multiple biopsy specimens were obtained from 18 current smokers, 24 former smokers, and 21 nonsmokers. Polymerase chain reaction-based assays involving 15 polymorphic microsatellite DNA markers were used to examine eight chromosomal regions for genetic changes (loss of heterozygosity [LOH] and microsatellite alterations). RESULTS: LOH and microsatellite alterations were observed in biopsy specimens from both current and former smokers, but no statistically significant differences were observed between the two groups. Among individuals with a history of smoking, 86% demonstrated LOH in one or more biopsy specimens, and 24% showed LOH in all biopsy specimens. About half of the histologically normal specimens from smokers showed LOH, but the frequency of LOH and the severity of histologic change did not correspond until the carcinoma in situ stage. A subset of biopsy specimens from smokers that exhibited either normal or preneoplastic histology showed LOH at multiple chromosomal sites, a phenomenon frequently observed in carcinoma in situ and invasive cancer. LOH on chromosomes 3p and 9p was more frequent than LOH on chromosomes 5q, 17p (17p13; TP53 gene), and 13q (13q14; retinoblastoma gene). Microsatellite alterations were detected in 64% of the smokers. No genetic alterations were detected in nonsmokers. CONCLUSIONS: Genetic changes similar to those found in lung cancers can be detected in the nonmalignant bronchial epithelium of current and former smokers and may persist for many years after smoking cessation.
Authors: L Thiberville; P Payne; J Vielkinds; J LeRiche; D Horsman; G Nouvet; B Palcic; S Lam Journal: Cancer Res Date: 1995-11-15 Impact factor: 12.701
Authors: B E Johnson; R I Linnoila; J P Williams; D J Venzon; P Okunieff; G B Anderson; G E Richardson Journal: J Clin Oncol Date: 1995-01 Impact factor: 44.544
Authors: Y Kishimoto; K Sugio; J Y Hung; A K Virmani; D D McIntire; J D Minna; A F Gazdar Journal: J Natl Cancer Inst Date: 1995-08-16 Impact factor: 13.506
Authors: Jennifer Beane; Jessica Vick; Frank Schembri; Christina Anderlind; Adam Gower; Joshua Campbell; Lingqi Luo; Xiao Hui Zhang; Ji Xiao; Yuriy O Alekseyev; Shenglong Wang; Shawn Levy; Pierre P Massion; Marc Lenburg; Avrum Spira Journal: Cancer Prev Res (Phila) Date: 2011-06
Authors: Vasiliy V Polosukhin; Justin M Cates; William E Lawson; Rinat Zaynagetdinov; Aaron P Milstone; Pierre P Massion; Sebahat Ocak; Lorraine B Ware; Jae Woo Lee; Russell P Bowler; Alexey V Kononov; Scott H Randell; Timothy S Blackwell Journal: Am J Respir Crit Care Med Date: 2011-04-21 Impact factor: 21.405
Authors: Adam M Gustafson; Raffaella Soldi; Christina Anderlind; Mary Beth Scholand; Jun Qian; Xiaohui Zhang; Kendal Cooper; Darren Walker; Annette McWilliams; Gang Liu; Eva Szabo; Jerome Brody; Pierre P Massion; Marc E Lenburg; Stephen Lam; Andrea H Bild; Avrum Spira Journal: Sci Transl Med Date: 2010-04-07 Impact factor: 17.956